Reason for request
Reassessment
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
eNrFmF1v2jAUhu/5FVHukxBaoJ0C1cbaDanVGC3atBvkJCfFzLFTf1DYr59D6EanRG1N3V0SJ+858Tl+zkuis3VOnBVwgRkduKHfdh2gCUsxvR24s5sL78Q9G7aiJVqhvdv6ftsPO66TECTEwC1X/RgQFf73q8uPoJ8H7g5bTsTiJSTy0X1KYuJ/RmJxhYryHidaMZw6OcgFSwduoeT2qhMJyXUWw3vGf4oCJRAFuyv7q8v58f71KCjFnqGqBPBLRG9rRYEaaSaKc6ByhCTcMr5pyPfISBuLKQimeAITJBcTzlY4hbQ2RIaIAKMg2X16DXxFQJZBasWDZZILI3G0ROsp3I3rk36vV0dyLb22F/b7nV7vqN897XVPjULxva2qr4J+iaCYHx33w5OwHQANYgKUQ+HFQBCVKEexl6OMpUxi6uWKSFwQ8PINEJYjwwpOGJeIWKodFqPH7WcpDoe7J3skxaIgaOMvRWG6VYgjvQxcQ8Lei5RvcMM1tojes3/0qSIkeGHWsx1ULGVcMmvEFJUNbLmYmm7EiFEJ6+aKmuFQrne9iEG8nuwvRutHwUTFBCem4NNoUiDkbDpu5t7bI+MDEjDj9pjxDdOU3YvXZ9F+7S1lX2xxWita8DScd05PemG3a3zUfuhGa5hW54qzAgJNKSwOgc+YZuxQ7OjerZd66Nw3btqts2IJItDgrTxDTulufbCC1s6DvbNWLdSKfjq/MW2irwr45nr7s1Yap4M/5TeDuI3JoFu2MfGXH4CKA1Zct+L1fFlIWYh3QbBAwhP6HIGf8f80IfZGt71/BVb8QeWXKspaSj2uxufza2h6Dp9yD4c64t3zO+ddG0NyBQfUoUK2NbCOz1+f1X/tsLW0J4/YYi/M1roiiRm1ZZZUXO+UDpoOuq70gms4fMky3PCFprEvo6D6OjRsRUH5ZWjY+g0C7h02
Wk0d7fz0cxD9wBdL
